Why Were the Checkpoint Inhibitors Developed into Drugs?
This seminar will be held using Zoom. Please register here: https://zoom.us/meeting/register/tJIkdO-rqzwsGtyGKaCW65anWJqcYkaCXzRC
The 2018 Nobel Prize announcement recognized the discovery of the “entirely new principle for cancer therapy” of negative immune regulation. It also cited the pharmaceutical industry’s lack of interest. Ultimately, a small biotech company developed both the anti-CTLA-4 antibody Yervoy/ipilimumab, based on James Allison’s work, and the anti-PD-1 antibody Opdivo/nivolumab based on Tasuku Honjo’s work. This talk will discuss why pharmaceutical companies were not interested, why these products were developed by the biotech company Medarex, and how this example highlights the results of new research into the origins of the most innovative medicines of the past two decades.
Date: 26 October 2020, 12:00 (Monday, 3rd week, Michaelmas 2020)
Venue: Kennedy Institute of Rheumatology, Headington OX3 7FY
Venue Details: This seminar will be held using Zoom. Please register here: https://zoom.us/meeting/register/tJIkdO-rqzwsGtyGKaCW65anWJqcYkaCXzRC
Speaker: Dr Donald Drakeman (Distinguished Research Professor, University of Notre Dame (US), and Fellow, Operations and Technology Management, Cambridge Judge Business School)
Organising department: Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS)
Organisers: Jennifer Pope (Kennedy Institute of Rheumatology), Professor Irina Udalova (Kennedy Institute of Rheumatology)
Organiser contact email address: jennifer.pope@kennedy.ox.ac.uk
Host: Professor Fiona Powrie (Kennedy Institute of Rheumatlogy)
Part of: Kennedy Institute Seminars
Booking required?: Required
Booking url: https://zoom.us/meeting/register/tJIkdO-rqzwsGtyGKaCW65anWJqcYkaCXzRC
Audience: Public
Editor: Jennifer Pope